The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Biology of HER2 and Its Importance in Breast Cancer
Abstract
Human epidermal growth factor receptor-2 (HER2/erbB-2) belongs to a family of four transmembrane receptors involved in signal transduction pathways that regulate cell growth and differentiation. Overexpression/amplification of HER2 is associated with malignancy and a poor prognosis in breast cancer. HER2 acts as a networking receptor that mediates signaling to cancer cells, causing them to proliferate. HER receptors exist as monomers but dimerize on ligand binding. HER ligands are bivalent growth factor molecules whose low-affinity site binds to HER2. No HER2-specific ligand has been identified but HER2 is the preferred heterodimerization partner for other HER receptors. HER2-containing heterodimers are relatively long-lived and potent. HER3 has no inherent activity and is the major and most potent dimerization partner of HER2. HER2 overexpression biases the formation of HER2-containing heterodimers, leading to enhanced responsiveness to stromal growth factors and oncogenic transformation. Removal of HER2 from the cell surface or inhibition of its intrinsic enzymatic activity may reduce oncogenicity. Our research suggests that the antitumor efficacy of HER2-specific antibodies such as Herceptin® relates to their ability to direct HER2 to a Cbl- dependent endocytosis and degradation pathway. The reported clinical therapeutic efficacy of anti-HER2 monoclonal antibodies in breast cancer highlights the importance of understanding the biology of HER2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Receptor Protein-Tyrosine Kinases and Their Signal Transduction Pathways
van der Geer, P., Hunter, T., & Lindberg, R. A. (1994) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.10.110194.001343 · Cited by 1,326
Multiple essential functions of neuregulin in development
Meyer, D., & Birchmeier, C. (1995) · Nature · doi:10.1038/378386a0 · Cited by 1,262
Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
Yamamoto, T., Ikawa, S., Akiyama, T., Semba, K., Nomura, N., Miyajima, N., Saito, T., & Toyoshima, K. (1986) · Nature · doi:10.1038/319230a0 · Cited by 1,204
The neu oncogene encodes an epidermal growth factor receptor-related protein
Bargmann, C. I., Hung, M.-C., & Weinberg, R. A. (1986) · Nature · doi:10.1038/319226a0 · Cited by 1,117
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,036
Self-citationLevkowitz, G., Waterman, H., Ettenberg, S. A., Katz, M., Tsygankov, A. Y., Alroy, I., Lavi, S., Iwai, K., Reiss, Y., Ciechanover, A., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80231-2 · Cited by 1,001
Self-citationRoss, J. S., & Fletcher, J. A. (1998) · STEM CELLS · doi:10.1002/stem.160413 · Cited by 985
The biology of erbB-2/nue/HER-2 and its role in cancer
Hynes, N. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90012-4 · Cited by 971
c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor
Levkowitz, G., Waterman, H., Zamir, E., Kam, Z., Oved, S., Langdon, W. Y., Beguinot, L., Geiger, B., & Yarden, Y. (1998) · Genes & Development · doi:10.1101/gad.12.23.3663 · Cited by 865
Self-citationOverexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
Berchuck, A., Kamel, A., Whitaker, R. S., Kerns, B. J., Olt, G. J., Kinney, R., Soper, J. T., Dodge, R. K., Clarke‐Pearson, D. L., & Marks, P. J. (1990) · PubMed · Cited by 860
Akiyama, T., Sudo, C., Ogawara, H., Toyoshima, K., & Yamamoto, T. (1986) · Science · doi:10.1126/science.3012781 · Cited by 796
Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00603.x · Cited by 769
Self-citationAlroy, I., & Yarden, Y. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00412-2 · Cited by 714
Self-citationInsect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.
Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., & Carraway, K. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8132 · Cited by 698 · cited 1×
“The HER3 receptor has only a weakly active kinase domain [Guy et al. 1994], and HER3 homodimers are mitogenically inactive [Pinkas-Kramarski et al. 1996].”
BackgroundErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E., & Yarden, Y. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00356.x · Cited by 674
Self-citationNonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
Sliwkowski, M. X., Schaefer, G., Akita, R. W., Lofgren, J. A., Fitzpatrick, V. D., Nuijens, A., Fendly, B. M., Cerione, R. A., Vandlen, R. L., & Carraway, K. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36676-0 · Cited by 643
(1996) · PubMed · Cited by 554
Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
Alimandi, M., Romano, A., Curia, M. C., Muraro, R., Fedi, P., Aaronson, S. A., Fiore, P. P. D., & Kraus, M. H. (1995) · PubMed · Cited by 548
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60784-8 · Cited by 540
Neuregulins and Their Receptors: A Versatile Signaling Module in Organogenesis and Oncogenesis
Burden, S., & Yarden, Y. (1997) · Neuron · doi:10.1016/s0896-6273(00)80324-4 · Cited by 476
Self-citationKlapper, L. N., Glathe, S., Vaisman, N., Hynes, N. E., Andrews, G. C., Sela, M., & Yarden, Y. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4995 · Cited by 455
Self-citationAll ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired
Baulida, J., Kraus, M. H., Alimandi, M., Fiore, P. P. D., & Carpenter, G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.9.5251 · Cited by 454
Recent Cancer Trends in the United States
Devesa, S. S., Blot, W. J., Stone, B. J., Miller, B. A., Tarone, R. E., & Fraumeni, J. F. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.3.175 · Cited by 420
Lenferink, A. E. G. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3385 · Cited by 413
Venter, D., Kumar, S., Tuzi, N., & Gullick, W. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92736-x · Cited by 404
FENDLY, B. M., Winget, M., Hudziak, R. M., Lipari, M. T., Napier, M. A., & Ullrich, A. (1990) · PubMed · Cited by 403
Drebin, J. A., Link, V. C., Stern, D. F., Weinberg, R. A., & Greene, M. I. (1985) · Cell · doi:10.1016/s0092-8674(85)80050-7 · Cited by 400
Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases
Carraway III, K. L., Weber, J. L., Unger, M. J., Ledesma, J., Yu, N., Gassmann, M., & Lai, C. (1997) · Nature · doi:10.1038/387512a0 · Cited by 394
van de Vijver, M., van de Bersselaar, R., Devilee, P., Cornelisse, C., Peterse, J., & Nusse, R. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.5.2019 · Cited by 330
Vennström, B., & Michael Bishop, J. (1982) · Cell · doi:10.1016/0092-8674(82)90383-x · Cited by 310
Kokai, Y., Myers, J. N., Wada, T., Brown, V. I., LeVea, C. M., Davis, J. G., Dobashi, K., & Greene, M. I. (1989) · Cell · doi:10.1016/0092-8674(89)90843-x · Cited by 309
Yang, Y., Spitzer, E., Meyer, D., Sachs, M., Niemann, C., Hartmann, G., Weidner, K. M., Birchmeier, C., & Birchmeier, W. (1995) · The Journal of cell biology · doi:10.1083/jcb.131.1.215 · Cited by 300
Bivalence of EGF-like ligands drives the ErbB signaling network
Tzahar, E. (1997) · The EMBO Journal · doi:10.1093/emboj/16.16.4938 · Cited by 228
Hancock, M. C., Langton-Webster, B. C., Chan, T., Toy, P., Monahan, J., Mischak, R. P., & Shawver, L. K. (1991) · PubMed · Cited by 225
Alternative Intracellular Routing of ErbB Receptors May Determine Signaling Potency
Waterman, H., Sabanai, I., Geiger, B., & Yarden, Y. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13819 · Cited by 207
Self-citationStancovski, I., Hurwitz, E., Leitner, O., Ullrich, A., Yarden, Y., & Sela, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8691 · Cited by 203
Self-citationThe ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands
Tzahar, E. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00032-2 · Cited by 191
Baselga, J. (2001) · Oncology · doi:10.1159/000055397 · Cited by 180
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.793 · Cited by 164
Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles.
Hung, M. C., Schechter, A. L., Chevray, P. Y., Stern, D. F., & Weinberg, R. A. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.2.261 · Cited by 159
The Predictive Value of HER2 in Breast Cancer
Piccart, M. J., Lohrisch, C. A., Leo, A. D., & Larsimont, D. (2001) · Oncology · doi:10.1159/000055405 · Cited by 155
Xia, W., Lau, Y. K. J., Zhang, H. Z., Liu, A. R., Li, L., Kiyokawa, N., Clayman, G. L., Katz, R. L., & Hung, M. (1997) · PubMed · Cited by 154
Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins.
Levkowitz, G., Klapper, L. N., Tzahar, E., Freywald, A., Sela, M., & Yarden, Y. (1996) · PubMed · Cited by 154
Self-citationKasprzyk, P. G., Song, S. U., Fiore, P. P. D., & King, C. R. (1992) · PubMed · Cited by 151
Hurwitz, E., Stancovski, I., Sela, M., & Yarden, Y. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3353 · Cited by 148
Self-citationErbB Tyrosine Kinases and the Two Neuregulin Families Constitute a Ligand-Receptor Network
Pinkas‐Kramarski, R., Shelly, M., Guarino, B. C., Wang, L. M., Lyass, L., Alroy, I., Alamandi, M., Kuo, A. H., Moyer, J. D., Lavi, S., et al. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.10.6090 · Cited by 145
Self-citationPinkas‐Kramarski, R., Eilam, R., Alroy, I., Levkowitz, G., Lonai, P., & Yarden, Y. (1997) · Oncogene · doi:10.1038/sj.onc.1201466 · Cited by 130
Self-citationJones, F. E., Dj, J., Guarino, B. C., Andrews, G. C., & Stern, D. F. (1996) · PubMed · Cited by 111
Receptor blockade with monoclomal antibodies as anti-cancer therapy
Baselga, J. M., & Mendelsohn, J. M. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90036-1 · Cited by 107
Waterman, H., Alroy, I., Strano, S., Seger, R., & Yarden, Y. (1999) · The EMBO Journal · doi:10.1093/emboj/18.12.3348 · Cited by 103
Self-citationColomer, R., Lupu, R., Bacus, S. S., & Gelmann, E. P. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.405 · Cited by 99
Zheng, F. F., Kuduk, S. D., Chiosis, G., Münster, P. N., Sepp‐Lorenzino, L., Danishefsky, S. J., & Rosen, N. X. (2000) · PubMed · Cited by 81
Akiyama, T., Saito, T., Ogawara, H., et al. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.3.1019 · Cited by 78
Oral cancer progression and c-erbB-2/neu proto-oncogene expression
Hou, L., Shi, D., Tu, S., Zhang, H.-Z., Hung, M., & Ling, D. (1992) · Cancer Letters · doi:10.1016/0304-3835(92)90234-m · Cited by 76
Lupu, R., Cardillo, M., Harris, L. N., Hijazi, M., & Rosenberg, K. E. (1995) · Seminars in Cancer Biology · doi:10.1006/scbi.1995.0016 · Cited by 65
c‐Cbl: A regulator of T cell receptor‐mediated signalling
Thien, C. B. F., & Langdon, W. Y. (1998) · Immunology and Cell Biology · doi:10.1046/j.1440-1711.1998.00768.x · Cited by 62
EGF-Related Peptides and Their Receptors in Mammary Gland Development
DiAugustine, R. P., Richards, R. G., & Sebastian, J. (1997) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1026395513038 · Cited by 61
EGF-Related Peptides in the Pathophysiology of the Mammary Gland
Normanno, N., & Ciardiello, F. (1997) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1026351730785 · Cited by 55
Connelly, P. A., & Stern, D. F. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.16.6054 · Cited by 50
Potter, C. R. D., Schelfhout, A., Verbeeck, P., Lakhani, S. R., Brünken, R., Schroeter, C. A., van den Tweel, J. G., Schauer, A., & Sloane, J. P. (1995) · Human Pathology · doi:10.1016/0046-8177(95)90163-9 · Cited by 35
Cooke, T. (2000) · European Journal of Oncology Nursing · doi:10.1054/ejon.2000.0072 · Cited by 14
Cited by
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors
Burgess, A. W., Cho, H.-S., Eigenbrot, C., Ferguson, K. M., Garrett, T. P. J., Leahy, D. J., Lemmon, M. A., Sliwkowski, M. X., Ward, C. W., & Yokoyama, S. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00350-2 · Cited by 909
The role of Notch in tumorigenesis: oncogene or tumour suppressor?
Radtke, F., & Raj, K. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1186 · Cited by 785
HER2: Biology, Detection, and Clinical Implications
Gutierrez, C., & Schiff, R. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0454-rar.1 · Cited by 652
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Ross, J. S., Fletcher, J. A., Linette, G. P., Stec, J., Clark, E., Ayers, M., Symmans, W. F., Pusztai, L., & Bloom, K. J. (2003) · The Oncologist · doi:10.1634/theoncologist.8-4-307 · Cited by 610
Metadata
- Authors
- Yarden, Y.
- Venue
- Oncology
- Publisher
- S. Karger AG
- Published
- 2001
- Volume
- 61
- Issue
- Suppl. 2
- Pages
- 1-13
- ISSN
- 0030-2414 (ISSN-L)
- 1423-0232
- OpenAlex
- W2036752075
- Cited by
- 737
- References
- 65
- FWCI
- 8.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.